PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19147827-6	2009	In both explanted fibroblasts and skin organ cultures, rosiglitazone prevented the stimulation of collagen gene transcription and cell migration elicited by TGF-beta.	Rosiglitazone	55-68	transforming growth factor, beta 1	Mus musculus	157-165	
25134730-11	2014	Moreover, rosiglitazone induced an increase in TGF-beta and IL-10 colocalization compared with the MPTPp treatment.	Rosiglitazone	10-23	transforming growth factor, beta 1	Mus musculus	47-55	
23646053-9	2013	However, rosiglitazone reduced only TGF-beta expression in obese mice, and even augmented VEGF expression in all types of mice.	Rosiglitazone	9-22	transforming growth factor, beta 1	Mus musculus	36-44	
28344789-8	2017	Rosiglitazone significantly decreased p-NF-kB p65 phosphorylation and TGFbeta protein expression at 24 and 72 hours post-irradiation and significantly decreased gene expression of Collagen1, Mmp13, Tnfalpha and Bax at 24 hours and p53 at 72 hours post-irradiation.	Rosiglitazone	0-13	transforming growth factor, beta 1	Mus musculus	70-77	
27877129-8	2016	We found that curcumin and rosiglitazone inhibited the proliferation and TGF-beta induced differentiation of mouse lung fibroblasts.	Rosiglitazone	27-40	transforming growth factor, beta 1	Mus musculus	73-81	
23885013-11	2013	Rosi treatment led to the further enlargement of adipocytes with improved metabolic activity in Lcn2(-/-) mice, which may be associated with a more pronounced effect of Rosi treatment in reducing TGF-beta in Lcn2(-/-) adipose tissue.	Rosiglitazone	0-4	transforming growth factor, beta 1	Mus musculus	196-204	
23885013-11	2013	Rosi treatment led to the further enlargement of adipocytes with improved metabolic activity in Lcn2(-/-) mice, which may be associated with a more pronounced effect of Rosi treatment in reducing TGF-beta in Lcn2(-/-) adipose tissue.	Rosiglitazone	169-173	transforming growth factor, beta 1	Mus musculus	196-204	
21836474-6	2011	Both pharmacological activation and overexpression of PPARgamma significantly inhibited TGF-beta1-induced extracellular matrix molecule expression in isolated cardiac fibroblasts, whereas treatment with the PPARgamma agonist rosiglitazone inhibited, and treatment with the PPARgamma antagonist T0070907 exacerbated chronic pressure overload-induced cardiac fibrosis and remodeling in wild-type mice in vivo.	Rosiglitazone	225-238	transforming growth factor, beta 1	Mus musculus	88-97	
19147827-7	2009	Rosiglitazone-driven adipogenic differentiation of both fibroblasts and preadipocytes was abrogated in the presence of TGF-beta; this effect was accompanied by the concomitant down-regulation of cellular PPAR-gamma mRNA expression.	Rosiglitazone	0-13	transforming growth factor, beta 1	Mus musculus	119-127	
18473419-10	2008	Rosiglitazone can also substantially reduce the hepatic expression of TGF-beta1, alpha-SMA type I and type III collagen in mice with liver fibrosis.	Rosiglitazone	0-13	transforming growth factor, beta 1	Mus musculus	70-79	
18991162-8	2009	Rosiglitazone significantly lowered serum ALT and AST and it reduced MCD-induced fibrosis by repressing levels of alpha-SMA protein expression and pro-fibrosis factors TGF-beta1 and CTGF.	Rosiglitazone	0-13	transforming growth factor, beta 1	Mus musculus	168-177	
18991162-11	2009	Rosiglitazone may ameliorate hepatic fibrosis by activating PPAR gamma, which can inhibit HSC activation and suppress TGF-beta1 and CTGF expression.	Rosiglitazone	0-13	transforming growth factor, beta 1	Mus musculus	118-127	
17260474-12	2006	The expressions of TGF-beta1, CTGF, and fibronectin in mice aged 20 weeks treated with rosiglitazone decreased by 37% , 21% , and 52% than same-aged control (P <0.	Rosiglitazone	87-100	transforming growth factor, beta 1	Mus musculus	19-28	
31561855-7	2019	Mechanistically, rosiglitazone reduced BDL-induced collagen content by downregulating fibrotic related genes including transforming growth factor beta1, alpha-smooth muscle actin and collagen type I alpha1, and decreased inflammation cytokine tumor necrosis factor alpha level by inhibiting phosphorylation of nuclear factor-kappaB in a PPARgamma-dependent manner.	Rosiglitazone	17-30	transforming growth factor, beta 1	Mus musculus	119-151